Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
Werte in diesem Artikel
For Immediate ReleaseChicago, IL – September 8, 2025 – Stocks in this week’s article are Halozyme Therapeutics, Inc. HALO, Leidos Holdings, Inc. LDOS and TransUnion TRU.Bet on These 3 Stocks with Upgraded Broker Ratings for Robust ReturnsStock markets have been hitting fresh records lately as investors gain confidence that the Federal Reserve will resume rate cuts this month. The softening labor market and rising inflation due to tariffs indicate a deteriorating macro environment, increasing the chance of rate cuts. Against such an investing backdrop, retail investors face significant challenges in selecting the right stocks and achieving strong returns.One way to cut short this task is to follow brokers' recommendations. In this regard, stocks like Halozyme Therapeutics, Inc., Leidos Holdings, Inc. and TransUnion are worth betting on.As brokers directly communicate with top management, they have more insight into what is happening in a particular company. They assess a company's publicly available documents and even attend conference calls. Brokers have a better understanding of the overall sector and industry. They place company fundamentals against the current economic backdrop to determine how a particular stock will fare as an investment.When brokers upgrade a stock, one can easily rely on their judgment. Yet, depending on broker upgrades is not enough to build your investment portfolio. A few other factors should be taken into account to ensure steady returns.3 Stocks with Upgraded Broker Ratings to BuySan Diego, CA-based Halozyme is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. HALO also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.Halozyme's 2025 earnings are expected to jump 46.1% year over year. HALO, which currently sports a Zacks Rank #1, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.Leidos, based IN Delaware, is a global science and technology leader that serves the defense, intelligence, civil and health markets. lDOS' core capabilities include providing solutions in the fields of cybersecurity, data analytics, enterprise IT modernization, operations and logistics, sensors, collection and phenomenology, software development and systems engineering.Leidos' 2025 earnings are projected to grow 9.2% on a year-over-year basis. LDOS, carrying a Zacks Rank #2 at present, has witnessed a 5.6% upward revision in broker ratings over the past four weeks.Based in Chicago, IL, TransUnion is one of the leading global providers of risk and information solutions to businesses and consumers. TRU provides consumer reports, risk scores, analytical services and decision-making capabilities to businesses.TransUnion's 2025 earnings are expected to rise 4.1% year over year. TRU, presently carrying a Zacks Rank #2, has witnessed a 5% upward revision in broker ratings over the past four weeks.Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.Click here to sign up for a free trial of the Research Wizard today.For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2747481/bet-on-these-3-stocks-with-upgraded-broker-ratings-for-robust-returnsDisclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.About Screen of the WeekZacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.Follow us on Twitter: https://www.twitter.com/zacksresearchJoin us on Facebook: https://www.facebook.com/ZacksInvestmentResearchZacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.Contact: Jim GiaquintoCompany: Zacks.comPhone: 312-265-9268Email: pr@zacks.comVisit: https://www.zacks.com/Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Leidos Holdings, Inc. (LDOS): Free Stock Analysis Report TransUnion (TRU): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Halozyme Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Halozyme Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Halozyme Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Leidos Holdings Inc
Analysen zu Leidos Holdings Inc
Datum | Rating | Analyst | |
---|---|---|---|
21.11.2017 | Leidos Hold | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
21.11.2017 | Leidos Hold | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Leidos Holdings Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen